CRANBURY, N.J., Aug. 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China. Palatin also announced that their South Korean licensee, Kwangdong Pharmaceuticals, completed enrollment in its Phase 3 clinical trial evaluating the efficacy and safety of Vyleesi in premenopausal women with HSDD. Data from this trial is anticipated by year end with a potential regulatory submission in the first half of 2024.
Pharmaceutical manufacturing sites have been taking root in Africa over the past year and Fosun Pharma is looking to establish a significant production site on the continent as well.
ABIDJAN, Côte d'Ivoire, June 6, 2023 /PRNewswire/ -- To support stronger healthcare delivery and outcomes in West Africa, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma or the Company, stock code: 600196.SH; 02196.HK) today announced a deepening partnership with IFC to help the company build a pharmaceutical production facility and distribution hub in Côte d'Ivoire.
China’s Fosun Pharma plans to build a facility in the Ivory Coast to manufacture anti-malaria drugs and antibacterial medicines with the help of a 100 million euro ($106 million) loan from the International Finance Corporation (IFC).
BEIJING, Jan 20 (Reuters) - Shanghai Fosun Pharmaceutical (600196.SS) said on Friday that it and Henan Genuine Biotech will cooperate with multiple companies to expand production of the COVID treatment Azvudine.
BEIJING, Jan 9 (Reuters) - Shanghai Fosun Pharmaceutical (600196.SS) said on Monday it would cooperate with its charity fund and Henan Genuine Biotech to donate 100 million yuan worth of COVID treatment Azvudine to China's rural areas.
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (US). This marks an important milestone for Fosun Pharma's development in the US.